1. Healthcare-associated pneumonia: <br/ > a. Prior to this illness, is known to have <br/ > been an inpatient in any healthcare <br/ > facility within the last 30 days <br/ > b. Resident of a nursing home or long-term <br/ > care facility. <br/ >2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment. <br/ >3. Previous participation in this REMAP within the last 90 days <br/ >4. Clinical or laboratory bleeding risk or both that is sufficient to contraindicate therapeutic anticoagulation, including intention to continue or commence dual anti-platelet therapy <br/ >5. Therapeutic anticoagulation is already present due to prior administration of any anticoagulant agent that is known or likely to still be active or a clinical decision has been made to commence therapeutic anticoagulation <br/ >6. Enrolment in a trial evaluating anticoagulation for proven or suspected COVID19 infection, where the protocol of that trial requires continuation of the treatment assignment specified in that trial <br/ >7. Known or suspected previous adverse reaction to UFH or LMWH including heparin induced thrombocytopenia (HIT).

1. Healthcare-associated pneumonia: <br/ > a. Prior to this illness, is known to have <br/ > been an inpatient in any healthcare <br/ > facility within the last 30 days <br/ > b. Resident of a nursing home or long-term <br/ > care facility. <br/ >2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment. <br/ >3. Previous participation in this REMAP within the last 90 days <br/ >4. Clinical or laboratory bleeding risk or both that is sufficient to contraindicate therapeutic anticoagulation, including intention to continue or commence dual anti-platelet therapy <br/ >5. Therapeutic anticoagulation is already present due to prior administration of any anticoagulant agent that is known or likely to still be active or a clinical decision has been made to commence therapeutic anticoagulation <br/ >6. Enrolment in a trial evaluating anticoagulation for proven or suspected COVID19 infection, where the protocol of that trial requires continuation of the treatment assignment specified in that trial <br/ >7. Known or suspected previous adverse reaction to UFH or LMWH including heparin induced thrombocytopenia (HIT).

N/A

N/A

1. Healthcare-associated pneumonia: <br/ > a. Prior to this illness, is known to have <br/ > been an inpatient in any healthcare <br/ > facility within the last 30 days <br/ > b. Resident of a nursing home or long-term <br/ > care facility. <br/ >2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment. <br/ >3. Previous participation in this REMAP within the last 90 days <br/ >4. Clinical or laboratory bleeding risk or both that is sufficient to contraindicate therapeutic anticoagulation, including intention to continue or commence dual anti-platelet therapy <br/ >5. Therapeutic anticoagulation is already present due to prior administration of any anticoagulant agent that is known or likely to still be active or a clinical decision has been made to commence therapeutic anticoagulation <br/ >6. Enrolment in a trial evaluating anticoagulation for proven or suspected COVID19 infection, where the protocol of that trial requires continuation of the treatment assignment specified in that trial <br/ >7. Known or suspected previous adverse reaction to UFH or LMWH including heparin induced thrombocytopenia (HIT).

1. Healthcare-associated pneumonia: <br/ > a. Prior to this illness, is known to have <br/ > been an inpatient in any healthcare <br/ > facility within the last 30 days <br/ > b. Resident of a nursing home or long-term <br/ > care facility. <br/ >2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment. <br/ >3. Previous participation in this REMAP within the last 90 days <br/ >4. Clinical or laboratory bleeding risk or both that is sufficient to contraindicate therapeutic anticoagulation, including intention to continue or commence dual anti-platelet therapy <br/ >5. Therapeutic anticoagulation is already present due to prior administration of any anticoagulant agent that is known or likely to still be active or a clinical decision has been made to commence therapeutic anticoagulation <br/ >6. Enrolment in a trial evaluating anticoagulation for proven or suspected COVID19 infection, where the protocol of that trial requires continuation of the treatment assignment specified in that trial <br/ >7. Known or suspected previous adverse reaction to UFH or LMWH including heparin induced thrombocytopenia (HIT).